BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Islet Sciences 

641 Lexington Avenue, 6th Floor

New York  New York  10022  U.S.A.
Phone: 646-863-6341 Fax: n/a


SEARCH JOBS




Industry
Biotechnology






 Company News
Islet Sciences Receives Notice Of Allowance For U.S. Patent Covering Novel IL-12 Inhibitors 8/6/2014 9:28:30 AM
Islet Sciences Announces Peer-Reviewed Publication Of Study Validating Novel Diabetes Diagnostic 7/16/2014 6:51:17 AM
Islet Sciences Highlights Remogliflozin Etabonate As Novel Treatment For Non-Alcoholic Steatohepatitis (NASH) 6/23/2014 7:15:48 AM
Islet Sciences To Present At The Joint Meeting Of The International Society Of Endocrinology And The Endocrine Society: ICE/ENDO 2014 6/18/2014 11:07:15 AM
Islet Sciences Presents Positive Clinical Results For Best-In-Class SGLT2 Inhibitor At American Diabetes Association Annual Meeting 6/16/2014 8:15:08 AM
Islet Sciences To Present At American Diabetes Association 6/12/2014 8:03:08 AM
Islet Sciences Appoints Steven Delmar As Chief Financial Officer 5/29/2014 6:54:53 AM
Islet Sciences Appoints William Wilkison, Ph.D. To Board Of Directors 4/21/2014 9:25:38 AM
Islet Sciences Announces Positive 12-Week Phase 2 Clinical Results For SGLT2 Inhibitor Remogliflozin Etabonate 4/17/2014 9:22:48 AM
Islet Sciences To Acquire BHV Pharma, Inc. And Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate Indicated For Type 2 Diabetes And NASH 3/13/2014 9:13:02 AM
1234